Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical lidocaine spray for postherpetic neuralgia
ACTRN12625001044415Phase 3Not yet recruiting
- Sponsor
- Andros Pharmaceuticals Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing Lidocaine spray with Placebo spray (2 arms). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lidocaine
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ACTRN12625001044415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001044415.